No­var­tis to ad­vance malar­ia pro­gram in­to PhI­II in bid to fight drug re­sis­tance

No­var­tis is mov­ing an an­ti-malar­ia drug in­to a Phase III tri­al that it hopes could pro­vide a new weapon against drug-re­sis­tant strains of the in­fec­tion.

The com­pa­ny and its Swiss non-prof­it part­ner Med­i­cines for Malar­ia Ven­ture, or MMV, an­nounced Wednes­day that they are mov­ing for­ward with the treat­ment, which us­es the ex­per­i­men­tal drug ganaplacide com­bined with a new for­mu­la­tion of cur­rent an­ti-malar­ia drug lume­fantrine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER